Financial Results for the quarter and year ended on March 31, 2026
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 4.3 pts more than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
MedPlus Health Services reported strong full-year FY26 results with consolidated revenue from operations of Rs. 68,924.66 million, up 12.3% from Rs. 61,360.53 million in FY25. Profit after tax grew significantly by 46.2% to Rs. 2,196.06 million from Rs. 1,502.33 million. For Q4 FY26 alone, revenue was Rs. 18,643.85 million and PAT was Rs. 639.73 million. The statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated financial results. The company also allotted 82,419 equity shares under its ESOP plan, bringing total paid-up capital to Rs. 240.11 million. Board changes include completion of tenure of two independent directors and appointment of two new independent directors.
The strong 46% PAT growth and clean audit opinion are positive signals for shareholders. The stock may see upward movement given robust profitability growth, though the 12% revenue growth is moderate.